Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOK | Q9UQ07 | 11/20 | 0.53 |
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24976095 | 1.00 | MOK (0.53) | MOKERN1GAAKDM4EHPGD | |
| SCHEMBL31428545 | 0.82 | GRM2 (0.40) | MOKGAAKDM4EHPGDALDH1A1 | |
| SCHEMBL24975640 | 0.82 | GRM2 (0.40) | MOKGAAKDM4EHPGDALDH1A1 | |
| SCHEMBL4731923 | 0.80 | NCF1 (0.62) | MOKGAAKDM4EHPGDHIF1A | |
| SCHEMBL31428728 | 0.80 | NCF1 (0.62) | MOKGAAKDM4EHPGDHIF1A | |
| SCHEMBL4735359 | 0.80 | CYP2A13 (0.55) | MOKGAAKDM4EHPGDHIF1A | |
| SCHEMBL24975496 | 0.80 | NCF1 (0.62) | MOKGAAKDM4EHPGDHIF1A | |
| SCHEMBL5093473 | 0.78 | NCF1 (0.64) | MOKGAAKDM4EHPGDALDH1A1 | |
| SCHEMBL31428429 | 0.77 | ALDH1A1 (0.68) | MOKGAAKDM4EHPGDALDH1A1 | |
| SCHEMBL31428850 | 0.74 | MOK (0.49) | MOKGAAKDM4EHIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | MOK 997/4885ERN1 1375/4885GAA 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.